Pharmacokinetics and Safety Profile of Tigecycline in Children Aged 8 to 11 Years With Selected Serious Infections: A Multicenter, Open-Label, Ascending-Dose Study

A tigecycline dosage of ∼1.2 mg/kg q12h may represent the most appropriate dosage for subsequent evaluation in Phase III clinical trials in children aged 8 to 11 years with selected serious bacterial infections. ClinicalTrials.gov identifier: NCT00488345.